US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 74.800
- +0.610+0.82%
Close May 3 16:00 ET
- 75.990
- +1.190+1.59%
Post 19:59 ET
3.55BMarket Cap-14193P/E (TTM)
76.320High74.360Low767.62KVolume75.570Open74.190Pre Close57.61MTurnover2.19%Turnover RatioLossP/E (Static)47.49MShares98.40052wk High18.60P/B2.62BFloat Cap55.02052wk Low--Dividend TTM35.00MShs Float109.940Historical High--Div YieldTTM2.64%Amplitude1.940Historical Low75.055Avg Price1Lot Size
Axsome Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -24.52%-145.08M | -10.15%-30.36M | -135.29%-53.55M | -65.04%-55.35M | 82.17%-5.82M | -7.66%-116.51M | 4.43%-27.56M | 15.01%-22.76M | -32.07%-33.54M | -19.98%-32.65M |
| Net income from continuing operations | -27.84%-239.24M | -61.09%-98.65M | -38.77%-62.2M | -62.09%-67.17M | 71.69%-11.22M | -43.50%-187.13M | -80.24%-61.24M | -28.50%-44.82M | -28.36%-41.44M | -35.45%-39.63M |
| Depreciation and amortization | 55.25%6.83M | 2.84%1.74M | 3.75%1.74M | 91.50%1.38M | 533.33%1.98M | 5,692.11%4.4M | 319.10%1.69M | 460.48%1.68M | 158.81%718K | 15.09%312K |
| Other non cash items | 1,000.44%53.1M | 878.29%44.21M | 156.22%1.03M | 7,553.85%7.75M | 1,212.50%105K | 395.38%4.83M | 332.72%4.52M | 76,911.49%402K | -46.29%-104K | 3,037.25%8K |
| Change In working capital | -219.95%-28.39M | -79.49%3.43M | -183.10%-8.96M | -360.26%-13.23M | -925.24%-9.63M | 7,205.56%23.67M | 1,725.71%16.7M | 418.26%10.79M | -334.02%-2.87M | 52.04%-939K |
| -Change in receivables | -51.52%-57.12M | 5.70%-16.41M | -166.21%-11.01M | -39.89%-22.62M | ---7.09M | ---37.7M | ---17.4M | ---4.13M | ---16.17M | --0 |
| -Change in inventory | 15.41%-4.46M | 60.45%-1.8M | 438.89%2.81M | -1,243.48%-1.05M | ---4.42M | -87,816.67%-5.28M | -976,029.03%-4.54M | -14,859.35%-828K | --92K | --0 |
| -Change in prepaid assets | -95.06%-5.34M | -307.74%-1.32M | 26.49%-888K | -181.33%-710K | -16.51%-2.42M | -2,755.34%-2.74M | -190.75%-323K | -3,601.25%-1.21M | 1,543.02%873K | -815.25%-2.08M |
| -Change in payables and accrued expense | -44.47%38.53M | -41.11%22.94M | -99.26%125K | -9.55%11.15M | 278.56%4.31M | 30,463.44%69.38M | 2,917.70%38.96M | 726.26%16.96M | 856.79%12.33M | 165.74%1.14M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -24.52%-145.08M | -10.15%-30.36M | -135.29%-53.55M | -65.04%-55.35M | 82.17%-5.82M | -7.66%-116.51M | 4.43%-27.56M | 15.01%-22.76M | -32.07%-33.54M | -19.98%-32.65M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 98.92%-582K | 96.13%-7K | -462.12%-371K | 99.75%-133K | 66.82%-71K | -17,335.71%-53.7M | -40,033.04%-181K | 74.49%-66K | -281,941.64%-53.24M | -613.45%-214K |
| Net PPE purchase and sale | 17.09%-582K | 96.13%-7K | -462.12%-371K | 44.81%-133K | 66.82%-71K | -127.92%-702K | -40,033.04%-181K | 74.49%-66K | -1,176.69%-241K | -613.45%-214K |
| Net business purchase and sale | --0 | --0 | --0 | ---- | ---- | ---53M | --0 | --0 | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 98.92%-582K | 96.13%-7K | -462.12%-371K | 99.75%-133K | 66.82%-71K | -17,335.71%-53.7M | -40,033.04%-181K | 74.49%-66K | -281,941.64%-53.24M | -613.45%-214K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 16.32%331.01M | -100.19%-2K | -81.14%33.37M | 226.09%246.08M | 65.79%51.57M | 2,456.89%284.58M | 54.32%1.07M | 40,236.64%176.95M | 3,727.96%75.46M | 287.36%31.1M |
| Net issuance payments of debt | 88.89%85M | --0 | --0 | -33.33%30M | --55M | --45M | --0 | --0 | --45M | --0 |
| Net common stock issuance | 6.15%258.75M | --0 | -81.27%33.75M | 591.22%225M | --0 | 3,178.15%243.76M | --0 | --180.2M | 2,868.62%32.55M | 407.03%31.01M |
| Proceeds from stock option exercised by employees | 98.67%12.42M | -59.53%1.15M | 40.89%4.32M | 3,632.95%6.57M | 112.64%387K | 42.00%6.25M | 159.27%2.83M | 598.45%3.06M | -81.65%176K | -90.49%182K |
| Net other financing activities | -141.14%-25.16M | 34.94%-1.15M | 25.65%-4.7M | -584.49%-15.49M | -4,194.38%-3.82M | -1,373.45%-10.43M | -182.54%-1.76M | ---6.32M | ---2.26M | ---89K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 16.32%331.01M | -100.19%-2K | -81.14%33.37M | 226.09%246.08M | 65.79%51.57M | 2,456.89%284.58M | 54.32%1.07M | 40,236.64%176.95M | 3,727.96%75.46M | 287.36%31.1M |
| Net cash flow | ||||||||||
| Beginning cash position | 132.26%200.84M | 83.09%416.56M | 495.57%437.11M | 191.02%246.52M | 132.26%200.84M | -52.97%86.47M | 98.49%227.52M | -48.03%73.39M | -48.56%84.71M | -52.97%86.47M |
| Current changes in cash | 62.06%185.35M | -13.84%-30.37M | -113.33%-20.55M | 1,784.62%190.6M | 2,687.71%45.67M | 217.42%114.37M | 5.23%-26.68M | 679.50%154.13M | 51.73%-11.31M | 90.82%-1.77M |
| End cash Position | 92.29%386.19M | 92.29%386.19M | 83.09%416.56M | 495.57%437.11M | 191.02%246.52M | 132.26%200.84M | 132.26%200.84M | 98.49%227.52M | -48.03%73.39M | -48.56%84.71M |
| Free cash flow | -24.27%-145.66M | -9.46%-30.37M | -136.24%-53.92M | -64.25%-55.48M | 82.07%-5.89M | -8.00%-117.21M | 3.80%-27.74M | 15.58%-22.82M | -32.92%-33.78M | -20.63%-32.87M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg